Endpoints in prostate cancer clinical trials

Urology

Volumn 60, Issue 3 SUPPL. 1, 2002, Pages 101-107

  Sartor, Oliver ^a  

^a Louisiana State University School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOXANTRONE; PROSTATE SPECIFIC ANTIGEN;

AGE; ARTICLE; BIOASSAY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COMORBIDITY; DISEASE COURSE; HISTORY; HORMONAL THERAPY; HUMAN; PATHOLOGY; PATIENT CARE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RISK FACTOR; TREATMENT OUTCOME;

EID: 0036756528     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)01585-6     Document Type: Article

References (29)

1. A.N. Serafini Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases Cancer 88 12 suppl 2000 2934 2939
2. I.F. Tannock D. Osoba M.R. Stockler Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant cancer a Canadian randomized trial with palliative end points J Clin Oncol 14 1996 1756 1764
3. R.R. Bahnson G.E. Hanks R.P. Huben NCCN practice guidelines for prostate cancer Oncology 14 2000 111 119
4. W.P. Witjes C.C. Schulman F.M. Debruyne Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal therapy in T2–3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer Urology 49 3A suppl 1997 65 69
5. A.L. Hanlon G.E. Hanks Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness American Society for Therapeutic Radiation and Oncology. Int J Radiat Oncol Biol Phys 46 2000 559 566
6. C.R. Pound A.W. Partin M.A. Eisenberger Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591 1597
7. M.S. Litwin K.A. McGuidan Accuracy of recall in health related quality of life assessment among men treated for prostate cancer J Clin Oncol 17 1999 2882 2888
8. M.S. Litwin D.J. Pasta J. Yu Urinary function and bother after radical prostatectomy or radiation for prostate cancer, multivariate quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor J Urol 164 2000 1973 1977
9. J.A. Talcott P. Rieker J.A. Clark Patient reported symptoms after primary therapy for early stage prostate cancer results of a prospective cohort study J Clin Oncol 16 1998 275 283
10. H. Schipper J. Clinch A. McMurray Measuring the quality of life of cancer patients the Functional Living Index-Cancer: development and validation J Clin Oncol 2 1986 472 483
11. C.L. Amling M.L. Blute E.J. Bergstralh Long term hazard of progression after radical prostatectomy for clinically localized prostate cancer continued risk of biochemical failure after 5 years J Urol 164 2000 101 105
12. M. Han A.W. Partin C.R. Pound Long term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15 year Johns Hopkins experience Urol Clin North Am 28 2001 555 565
13. E.J. Small A. McMillan M. Meyer Serum prostate-specific antigen decline as a marker for of clinical outcome in hormone-refractory prostate cancer patients association with progression free survival, pain end points, survival J Clin Oncol 19 2001 1304 1311
14. C. Palmberg P. Koivisto T. Visakorpi PSA decline is an independent prognostic marker in hormonally treated prostate cancer Eur Urol 36 1999 191 196
15. G.J. Bubley M. Carducci W. Dahut Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 17 1999 3461 3467
16. P. Therasse S.G. Arbuck E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
17. P.N. Post B.E. Hansen P.J. Kil The independent prognostic value of co-morbidity among men aged <75 years with localized prostate cancer a population based study BJU Int 87 2001 821 826
18. M.W. Kattan J.A. Eastham A.M. Stapleton A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer J Natl Cancer Inst 90 1998 766 771
19. A.V. D’Amico R. Whittington S.B. Malkowicz Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external beam radiation therapy for clinically localized prostate cancer J Clin Oncol 17 1999 168 172
20. M. Roach III A. Chen J. Song Pretreatment prostate specific antigen and Gleason score predict the risk of extracapsular extension and the risk of failure following radiotherapy in patients with clinically localized prostate cancer Semin Urol Oncol 18 2000 108 114
21. A.V. D’Amico R. Whittington S.B. Malkowicz Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer J Clin Oncol 18 2000 1164 1172
22. T. Bjork H. Lilja A. Christensson The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer BJU Int 84 1999 1021 1027
23. O. Bratt A. Borg U. Krisofferson CAG repeat length in the androgen receptor gene is related to age of at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk Br J Cancer 81 1999 672 676
24. E.M. Messing J. Manola M. Sarosdy Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer N Engl J Med 341 1999 1781 1788
25. M.V. Pilepich K. Winter M.J. John Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252
26. C.A. Lawton K. Winter K. Murray Updated results of the phase III radiation therapy oncology group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate Int J Radiat Oncol Biol Phys 49 2001 937 946
27. M. Bolla D. Gonzalez P. Warde Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 1997 295 300
28. R.L. Leibowitz S.J. Tucker Treatment of localized prostate cancer with intermittent triple androgen blockade preliminary results in 110 consecutive patients Oncologist 6 2001 177 182
29. J. Wang S. Halford A. Rigg Adjuvant mitoxantrone chemotherapy in advanced prostate cancer BJU Int 86 2000 675 680